

CITATION REPORT

List of articles citing

Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond

DOI: 10.1038/nrd2030

Nature Reviews Drug Discovery, 2006, 5, 689-702.

Source: <https://exaly.com/paper-pdf/40436822/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 419 | The Repurposing Drugs in Oncology (ReDO) Project. 2014 , 8, 442 | | 89 |
| 418 | Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. 2007 , 76, 915-23 | | 106 |
| 417 | Phosphodiesterase type 5: expanding roles in cardiovascular regulation. 2007 , 101, 1084-95 | | 164 |
| 416 | Emerging therapies for pulmonary arterial hypertension. 2007 , 16, 803-18 | | 12 |
| 415 | Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. 2007 , 115, 2331-9 | | 118 |
| 414 | Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report. 2007 , 1, 46 | | 20 |
| 413 | A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour. 2007 , 27, 255-9 | | 49 |
| 412 | [Oral sildenafil in neonatal medicine: "tested in adults also used in neonates"]. 2007 , 66, 167-76 | | 7 |
| 411 | Sildenafil: A recent advance in the treatment of pulmonary arterial hypertension. 2007 , 2, 61-68 | | |
| 410 | Ambrisentan. <i>Nature Reviews Drug Discovery</i> , 2007 , 6, 697-8 | 64.1 | 6 |
| 409 | Thinking inside the box. To cope with an increasing disease burden, drug discovery needs biologically relevant and predictive testing systems. 2007 , 8 Spec No, S40-3 | | 11 |
| 408 | Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. 2007 , 150, 538-40 | | 22 |
| 407 | Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. 2007 , 52, 990-1005 | | 45 |
| 406 | Sildenafil citrate concentrations not affecting oxidative phosphorylation depress H ₂ O ₂ generation by rat heart mitochondria. 2008 , 309, 77-85 | | 41 |
| 405 | Phosphodiesterase 5 inhibition in essential hypertension. 2008 , 10, 52-7 | | 27 |
| 404 | Modulation of the NO/cGMP pathway reduces the vasoconstriction induced by acellular and PEGylated haemoglobin. 2008 , 1784, 1428-34 | | 5 |
| 403 | PDE5 inhibitors and pulmonary hypertension. 2008 , 5, 171-178 | | |

| | | |
|-----|--|-----|
| 402 | Sildenafil reduces alcohol-induced gastric damage: just say 'NO'. 2008 , 153, 623-4 | 9 |
| 401 | Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. 2008 , 20, 2231-6 | 74 |
| 400 | Cyclic nucleotide-specific phosphodiesterases of Plasmodium falciparum: PfpDEalpha, a non-essential cGMP-specific PDE that is an integral membrane protein. 2008 , 38, 1625-37 | 35 |
| 399 | The role of users in innovation in the pharmaceutical industry. 2008 , 13, 353-9 | 37 |
| 398 | Failure is an option: learning from unsuccessful proof-of-concept trials. 2008 , 13, 913-6 | 26 |
| 397 | Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. 2008 , 12, 2651-64 | 66 |
| 396 | Oral phosphodiesterase type 5 inhibitors: nonrectogenic beneficial uses. 2008 , 5, 2502-18 | 37 |
| 395 | Sildenafil: a review of its use in pulmonary arterial hypertension. 2008 , 68, 383-97 | 50 |
| 394 | Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. 2008 , 20, 202-12 | 104 |
| 393 | Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. 2008 , 21, 824-32 | 57 |
| 392 | Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. 2008 , 48, 926-34 | 86 |
| 391 | Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. 2008 , 283, 29572-85 | 153 |
| 390 | Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. 2008 , 326, 380-7 | 48 |
| 389 | Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. 2008 , 178, 188-96 | 66 |
| 388 | G protein-coupled receptor connectivity to NF-kappaB in inflammation and cancer. 2008 , 27, 320-50 | 52 |
| 387 | Viagra and wound healing: the NO connection. 2008 , 21, 106, 108-9 | 13 |
| 386 | The Drug Discovery Business to Date. 2008 , 1-52 | 1 |
| 385 | Out of the blue. 2009 , 2, 67-71 | |

| | | |
|-----|--|-----|
| 384 | The effects of vasodilators in pulmonary hypertension: pulmonary vascular or peripheral vascular?. 2009 , 2, 145-50 | 19 |
| 383 | The commonly used cGMP-dependent protein kinase type I (cGKI) inhibitor Rp-8-Br-PET-cGMPS can activate cGKI in vitro and in intact cells. 2009 , 284, 556-562 | 35 |
| 382 | Erectile dysfunction following prostatectomy: prevention and treatment. 2009 , 6, 415-27 | 72 |
| 381 | Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. 2009 , 82, 30-9 | 56 |
| 380 | Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 2009 , 6, 349-55 | 25 |
| 379 | Review of drug treatment for female sexual dysfunction. 2009 , 20, 671-4 | 13 |
| 378 | NO- and haem-independent soluble guanylate cyclase activators. 2009 , 309-39 | 108 |
| 377 | Therapeutic targets in pulmonary arterial hypertension. 2009 , 121, 69-88 | 71 |
| 376 | Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. 2009 , 4, 853-65 | 130 |
| 375 | Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. 2009 , 25, 136-43 | 17 |
| 374 | Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. 2009 , 26, 813-25 | 75 |
| 373 | [Therapy of pulmonary arterial hypertension]. 2009 , 50, 1101-2, 1104-9 | 2 |
| 372 | Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion. 2009 , 90, 454-62 | 50 |
| 371 | Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity. 2009 , 28, 1537-50 | 59 |
| 370 | Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. 2009 , 30, 1-24 | 45 |
| 369 | Lipid nanocapsules: a new platform for nanomedicine. 2009 , 379, 201-9 | 375 |
| 368 | Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors. 2009 , 19, 4088-91 | 21 |
| 367 | Biochemical Detection of cGMP From Past to Present: An Overview. 2009 , 195-228 | 10 |

| | | |
|-----|--|-----|
| 366 | Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. 2009 , 46, 560-7 | 39 |
| 365 | Induction of PDE5 and de-sensitization to endogenous NO signaling in a systemic resistance artery under altered blood flow. 2009 , 47, 57-65 | 11 |
| 364 | Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. 2009 , 361, 1864-71 | 167 |
| 363 | Drug repositioning using in silico compound profiling. 2009 , 1, 1723-36 | 25 |
| 362 | NO-independent, haem-dependent soluble guanylate cyclase stimulators. 2009 , 277-308 | 152 |
| 361 | A chemical proteomics based enrichment technique targeting the interactome of the PDE5 inhibitor PF-4540124. 2009 , 5, 472-82 | 27 |
| 360 | Aktuelle Therapie der pulmonal-arteriellen Hypertonie. 2010 , 7, 192-199 | |
| 359 | Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. 2010 , 3, 507-15 | 38 |
| 358 | Repurposing an old anti-fungal drug as a Hedgehog inhibitor. 2010 , 1, 417-8 | 2 |
| 357 | Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). 2010 , 14, 2190-9 | 208 |
| 356 | Target profiling of a small library of phosphodiesterase 5 (PDE5) inhibitors using chemical proteomics. 2010 , 5, 1927-36 | 17 |
| 355 | Improved method for the determination of cyclic guanosine monophosphate (cGMP) in human plasma by LC-MS/MS. 2010 , 878, 487-91 | 14 |
| 354 | KMUP-1 attenuates serum deprivation-induced neurotoxicity in SH-SY5Y cells: roles of PKG, PI3K/Akt and Bcl-2/Bax pathways. 2010 , 268, 46-54 | 27 |
| 353 | [PDE5 inhibitors in the treatment of pulmonary hypertension]. 2010 , 39, 391-6 | 1 |
| 352 | Testosterone and chronic sildenafil/tadalafil anti-apoptotic role in aged diabetic rats. 2010 , 22, 255-61 | 25 |
| 351 | Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscles cells. 2010 , 37, 362-7 | 16 |
| 350 | Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms. 2010 , 77, 670-7 | 18 |
| 349 | A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction. 2010 , 2010, | 17 |

| | | |
|-----|---|-----|
| 348 | Development and validation of a transcriber assay for detection of AMP- and GMP-producing enzymes. 2010 , 8, 344-55 | 27 |
| 347 | Update on pulmonary hypertension 2009. 2010 , 181, 1020-6 | 12 |
| 346 | Phosphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?. 2010 , 120, 746-51 | 17 |
| 345 | Sildenafil promotes adipogenesis through a PKG pathway. 2010 , 396, 1054-9 | 53 |
| 344 | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. 2010 , 11, 1109-22 | 63 |
| 343 | Riociguat for pulmonary hypertension. 2010 , 6, 155-66 | 24 |
| 342 | Targeting cancer with phosphodiesterase inhibitors. 2010 , 19, 117-31 | 105 |
| 341 | Mechanisms of disease: pulmonary arterial hypertension. 2011 , 8, 443-55 | 472 |
| 340 | Synthesis and molecular modeling of novel tetrahydro- β -carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. 2011 , 54, 495-509 | 39 |
| 339 | Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure. 2011 , 45, 1551-8 | 11 |
| 338 | Riociguat for the treatment of pulmonary hypertension. 2011 , 20, 567-76 | 69 |
| 337 | Sildenafil inhibits calcineurin/NFATc2-mediated cyclin A expression in pulmonary artery smooth muscle cells. 2011 , 89, 644-9 | 8 |
| 336 | Phosphodiesterase inhibitors: history of pharmacology. 2011 , 1-46 | 27 |
| 335 | Signal transduction in <i>Trypanosoma cruzi</i> . 2011 , 75, 325-44 | 13 |
| 334 | Cyclic Nucleotides and Nucleotide Cyclases in Plant Stress Responses. 2011 , | 6 |
| 333 | Treatment of Heart Failure with a Preserved Ejection Fraction. 2011 , 704-715 | |
| 332 | Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium. 2011 , 6, e27910 | 20 |
| 331 | Modern drug discovery technologies: opportunities and challenges in lead discovery. 2011 , 14, 830-9 | 31 |

| | | |
|-----|--|-----|
| 330 | Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in men. 2011 , 8, 109-118 | 2 |
| 329 | Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. 2011 , 19, 45-57 | 164 |
| 328 | Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension. 2011 , 12, 58 | 4 |
| 327 | Sildenafil accelerates fracture healing in mice. 2011 , 29, 867-73 | 39 |
| 326 | N-Acylhydrazones as inhibitors of PDE10A. 2011 , 21, 4155-9 | 26 |
| 325 | Cyclic GMP signaling in rat urinary bladder, prostate, and epididymis: tissue-specific changes with aging and in response to Leydig cell depletion. 2011 , 142, 333-43 | 17 |
| 324 | Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. 2011 , 4, 198-206 | 44 |
| 323 | The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. 2011 , 3, 80ps16 | 288 |
| 322 | Targeting dimethylarginine dimethylaminohydrolases in pulmonary arterial hypertension: a new approach to improve vascular dysfunction?. 2011 , 123, 1156-8 | 3 |
| 321 | Sildenafil has little influence on cardiovascular hemodynamics or 6-km time trial performance in trained men and women at simulated high altitude. 2011 , 12, 215-22 | 18 |
| 320 | Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. 2011 , 108, 17111-6 | 255 |
| 319 | Differential expression of PDE5 in failing and nonfailing human myocardium. 2012 , 5, 79-86 | 60 |
| 318 | A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. 2012 , 125, 324-34 | 265 |
| 317 | Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?. 2012 , 32, 1343-53 | 75 |
| 316 | Drug repositioning for personalized medicine. 2012 , 4, 27 | 144 |
| 315 | Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms. 2012 , 97, 370-9 | 49 |
| 314 | Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the activity of two atypical antidepressant drugs, mianserin and tianeptine, in the forced swim test in mice. 2012 , 38, 121-6 | 11 |
| 313 | Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. 2012 , 22, 5903-8 | 28 |

| | | |
|-----|--|----|
| 312 | Influence of the phosphodiesterase type 5 inhibitor, sildenafil, on antidepressant-like activity of magnesium in the forced swim test in mice. 2012 , 64, 205-11 | 9 |
| 311 | Drug Repositioning: The Business Case and Current Strategies to Repurpose Shelved Candidates and Marketed Drugs. 2012 , 7-32 | 5 |
| 310 | Identifying novel drug indications through automated reasoning. 2012 , 7, e40946 | 13 |
| 309 | PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis. 2012 , 3, 167 | 22 |
| 308 | PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells. 2012 , 113, 2738-43 | 21 |
| 307 | Natural Products as Lead Compounds in Medicinal Chemistry. 2012 , 81-126 | 1 |
| 306 | Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the antidepressant activity of amitriptyline but not desipramine, in the forced swim test in mice. 2012 , 119, 645-52 | 15 |
| 305 | Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb Pro: formulation aspects and nanoparticle stability to nebulization. 2012 , 422, 398-408 | 53 |
| 304 | Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries. 2012 , 674, 345-51 | 17 |
| 303 | Melanoma-induced immunosuppression and its neutralization. 2012 , 22, 319-26 | 89 |
| 302 | Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not. 2012 , 349, 145-53 | 11 |
| 301 | Novel therapies in acute and chronic heart failure. 2012 , 135, 1-17 | 42 |
| 300 | Development of a biodegradable nanoparticle platform for sildenafil: formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters. 2012 , 157, 469-77 | 45 |
| 299 | Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. 2012 , 61, 275-282 | 50 |
| 298 | Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. 2013 , 9, 1193-205 | 19 |
| 297 | Novel medical therapies for pulmonary arterial hypertension. 2013 , 34, 867-80 | 9 |
| 296 | Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. 2013 , 11, 222-9 | 24 |
| 295 | Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction. 2013 , 13, 189-96 | 28 |

| | | |
|-----|---|-----|
| 294 | The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis. 2013 , 229, 242-9 | 29 |
| 293 | Computational drug repositioning: from data to therapeutics. 2013 , 93, 335-41 | 257 |
| 292 | Inhalation Drug Delivery. 2013 , 1-14 | 5 |
| 291 | Translational medicine: mitigating risks for investigators. <i>Nature Reviews Drug Discovery</i> , 2013 , 12, 327-864.1 | 4 |
| 290 | Tumor microenvironment and myeloid-derived suppressor cells. 2013 , 6, 169-77 | 90 |
| 289 | Sildenafil provides sustained neuroprotection in the absence of learning recovery following the 4-vessel occlusion/internal carotid artery model of chronic cerebral hypoperfusion in middle-aged rats. 2013 , 90, 58-65 | 12 |
| 288 | Update on Drug Interactions With Phosphodiesterase-5 Inhibitors Prescribed as First-Line Therapy for Patients with Erectile Dysfunction or Pulmonary Hypertension. 2013 , 14, 265-269 | 20 |
| 287 | Signal transduction in the development of pulmonary arterial hypertension. 2013 , 3, 278-93 | 61 |
| 286 | The first Keystone Symposia Conference on pulmonary vascular disease and right ventricular dysfunction: Current concepts and future therapies. 2013 , 3, 275-7 | 2 |
| 285 | Drugs in search of diseases. 2013 , 5, 186fs18 | 12 |
| 284 | Effect of sildenafil citrate on the structure of rat liver. 2013 , 36, 991-1003 | |
| 283 | Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. 2013 , 4, 3-11 | 80 |
| 282 | Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. 2014 , 10, 825-39 | 21 |
| 281 | Sildenafil Inhibits Advanced Glycation End Products-induced sFlt-1 Release Through Upregulation of Heme Oxygenase-1. 2014 , 20, 57-68 | 4 |
| 280 | PKG-1 leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension. 2014 , 307, L537-44 | 14 |
| 279 | Stimulation of neural stem cell proliferation by inhibition of phosphodiesterase 5. 2014 , 2014, 878397 | 18 |
| 278 | Quantification of active pharmaceutical ingredient and impurities in sildenafil citrate obtained from the Internet. 2014 , 5, 180-9 | 7 |
| 277 | Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives. 2014 , 2014, 878670 | 51 |

| | | |
|-----|--|----------|
| 276 | New approaches to the design and discovery of therapies to prevent erectile dysfunction. 2014 , 9, 1447-69 | 10 |
| 275 | Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. 2014 , 174, 964-70 | 87 |
| 274 | Safety of sildenafil in infants*. 2014 , 15, 362-8 | 29 |
| 273 | The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. 2014 , 2014, 257-90 | 10 |
| 272 | Advances in targeting cyclic nucleotide phosphodiesterases. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 290-314 | 64.1 488 |
| 271 | Preparation of sildenafil citrate microcapsules and in vitro/in vivo evaluation of taste masking efficiency. 2014 , 466, 286-95 | 33 |
| 270 | Thrombosis, platelets, microparticles and PAH: more than a clot. 2014 , 19, 1230-5 | 33 |
| 269 | Therapeutic Drug Development and Human Clinical Trials. 2014 , 315-330 | |
| 268 | Exploiting large-scale drug-protein interaction information for computational drug repurposing. 2014 , 15, 210 | 13 |
| 267 | The current approach into signaling pathways in pulmonary arterial hypertension and their implication in novel therapeutic strategies. 2014 , 66, 552-64 | 6 |
| 266 | Understanding adverse drug reactions: An overview. 2014 , 12, 189-195 | 4 |
| 265 | Metal-Free Intramolecular Alkyne-Azide Cycloaddition To Construct the Pyrazolo[4,3-f][1,2,3]triazolo[5,1-c][1,4]oxazepine Ring System. 2015 , 2015, 5663-5670 | 18 |
| 264 | Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension. 2015 , 83, 659-70 | 1 |
| 263 | Ventricular fibrillation development following atrial fibrillation after the ingestion of sildenafil in a patient with Wolff-Parkinson-White syndrome. 2015 , 4, 159-61 | 0 |
| 262 | Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children. 2015 , 14, 633-42 | 3 |
| 261 | Angina treatments and prevention of cardiac events: an appraisal of the evidence. 2015 , 17, G10-G18 | 6 |
| 260 | Cilostazol but not sildenafil prevents memory impairment after chronic cerebral hypoperfusion in middle-aged rats. 2015 , 283, 61-8 | 15 |
| 259 | Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. 2015 , 1001, 35-40 | 12 |

| | | |
|-----|---|----------|
| 258 | Shedding of the tumor necrosis factor (TNF) receptor from the surface of hepatocytes during sepsis limits inflammation through cGMP signaling. 2015 , 8, ra11 | 37 |
| 257 | Academic drug discovery: current status and prospects. 2015 , 10, 937-44 | 33 |
| 256 | Perioperative management of patients with pulmonary hypertension for non-cardiac surgery. 2015 , 17, 15 | 10 |
| 255 | The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. 2015 , 34, 286-93 | 52 |
| 254 | Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. 2015 , 4, e998519 | 67 |
| 253 | PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. 2015 , 50, 434-41 | 41 |
| 252 | Strategies to increase nitric oxide signalling in cardiovascular disease. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 623-41 | 64.1 312 |
| 251 | Drug repurposing in oncology--patient and health systems opportunities. 2015 , 12, 732-42 | 180 |
| 250 | Preclinical safety evaluation of submicronized sildenafil citrate nebulization solution in small experimental animals. 2015 , 41, 450-8 | 1 |
| 249 | PDE5 inhibition improves acquisition processes after learning via a central mechanism. 2015 , 97, 233-9 | 15 |
| 248 | Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. 2015 , 131, 289-99 | 118 |
| 247 | Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. 2015 , 21, e25-50 | 87 |
| 246 | Bioinorganic elemental content of the Ghanaian aphrodisiac medicinal plant, <i>Paullina pinnata</i> Linn. (Sapindaceae). 2016 , 10, 206-211 | |
| 245 | Therapeutic Effects of Sildenafil on Experimental Mandibular Fractures. 2016 , 27, 615-20 | 6 |
| 244 | Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension. 2016 , 57, 466-72 | 16 |
| 243 | Drug Discovery Methods. 2016 , 63-95 | 4 |
| 242 | Reverse-phase high-performance liquid chromatography for the simultaneous determination of sildenafil and N-desmethyl sildenafil in plasma of children. 2016 , 30, 2070-2073 | 5 |
| 241 | Drug therapy for erectile dysfunction. 2016 , 172-193 | |

| | | |
|-----|---|-----|
| 240 | The maintenance ability and Ca availability of skeletal muscle are enhanced by sildenafil. 2016 , 48, e278 | 4 |
| 239 | In silico drug repositioning for the treatment of Alzheimer's disease using molecular docking and gene expression data. 2016 , 6, 98080-98090 | 7 |
| 238 | Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases. 2016 , 279, 315-36 | 111 |
| 237 | Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. 2016 , 115, 895-900 | 24 |
| 236 | Serendipity. 2016 , 388-414 | |
| 235 | Neurovascular Protective Function of Endothelial Nitric Oxide - Recent Advances. 2016 , 80, 1499-503 | 34 |
| 234 | Update on novel targets and potential treatment avenues in pulmonary hypertension. 2016 , 311, L811-L831 | 14 |
| 233 | Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth. 2016 , 14, 2599-610 | 49 |
| 232 | Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension. 2016 , 12, 63-8 | 13 |
| 231 | Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing. 2016 , 68, 191-200 | 28 |
| 230 | Potential of the isolated lung technique for the examination of sildenafil absorption from lung-delivered poly(lactide-co-glycolide) microparticles. 2016 , 226, 15-20 | 10 |
| 229 | Drugs for Treatment of Erectile Dysfunction. 2016 , 783-800 | |
| 228 | Drug Repurposing for the Development of Novel Analgesics. 2016 , 37, 172-183 | 37 |
| 227 | Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer. 2016 , 35, 3965-75 | 38 |
| 226 | A Phase I proof-of-concept and safety trial of sildenafil to treat cerebral vasospasm following subarachnoid hemorrhage. 2016 , 124, 318-27 | 12 |
| 225 | Formulation and process considerations for the design of sildenafil-loaded polymeric microparticles by vibrational spray-drying. 2017 , 22, 691-698 | 8 |
| 224 | Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis?. 2017 , 144, 117-123 | 13 |
| 223 | ATR-FTIR characterization of generic brand-named and counterfeit sildenafil- and tadalafil-based tablets found on the Brazilian market. 2017 , 57, 283-295 | 20 |

| | | |
|-----|--|----|
| 222 | Gasotransmitters: expanding the kinetic universe of cell signaling. 2017 , 312, C1-C2 | 2 |
| 221 | Classical activation of macrophages and vardenafil. 2017 , 131, 1141-1145 | 1 |
| 220 | Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases. 2017 , 22, 805-813 | 14 |
| 219 | Potential of the NO-cGMP pathway and blood flow responses during dynamic exercise in healthy humans. 2017 , 117, 237-246 | 4 |
| 218 | Host-guest interactions between sildenafil and cyclodextrins: Spectrofluorometric study and molecular dynamic modeling. 2017 , 77, 115-120 | 1 |
| 217 | PDE 5 inhibitor improves insulin sensitivity by enhancing mitochondrial function in adipocytes. 2017 , 493, 631-636 | 8 |
| 216 | RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. 2017 , 50, | 74 |
| 215 | Phosphodiesterases and preeclampsia. 2017 , 108, 94-100 | 3 |
| 214 | Strategies for Tackling Drug Resistance in Tuberculosis. 2017 , 89-112 | 1 |
| 213 | Smooth Muscle Phenotypic Diversity: Effect on Vascular Function and Drug Responses. 2017 , 78, 383-415 | 1 |
| 212 | When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data. 2017 , 15, 354-361 | 2 |
| 211 | Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies. 2017 , 38, 39-48 | 22 |
| 210 | Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine. 2017 , 2, 311-327 | 42 |
| 209 | Holistic Drug Targeting. 2017 , 65-88 | 3 |
| 208 | Complex Pathophysiology of Pulmonary Hypertension Associated with Systemic Sclerosis: Potential Unfavorable Effects of Vasodilators. 2017 , 2, 92-99 | 5 |
| 207 | Sildenafil in Infants and Children. 2017 , 4, | 8 |
| 206 | Demonstration Study: A Protocol to Combine Online Tools and Databases for Identifying Potentially Repurposable Drugs. 2017 , 2, 15 | 1 |
| 205 | Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension. 2017 , 2017, 8381653 | 19 |

| | | |
|-----|---|-----|
| 204 | Synthesis and Antiviral Activity of Sulfonohydrazide and 1,3,4-Oxadiazole Derivatives of 6,6-Dimethyl-9-Oxo-4,5,6,7,8,9-Hexahydropyrazolo[5,1-b] Quinazoline. 2017 , 41, 221-224 | 5 |
| 203 | Aphrodisiac potentials of the ethanol extract of <i>Aloe barbadensis</i> Mill. root in male Wistar rats. 2017 , 17, 360 | 13 |
| 202 | Do Statins Improve Survival in Small-Cell Lung Cancer?. 2017 , 35, 1497-1498 | 3 |
| 201 | Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?. 2018 , 104, 1244-1250 | 43 |
| 200 | Sildenafil protects neuronal cells from mitochondrial toxicity induced by amyloid peptide via ATP-sensitive K channels. 2018 , 500, 504-510 | 13 |
| 199 | Sildenafil, a phosphodiesterase-5 inhibitor, offers protection against carbon tetrachloride-induced hepatotoxicity in rat. 2018 , 29, 29-35 | 4 |
| 198 | A bibliometric review of drug repurposing. 2018 , 23, 661-672 | 115 |
| 197 | Structural-Activity Relationship of Ginsenosides from Steamed Ginseng in the Treatment of Erectile Dysfunction. 2018 , 46, 137-155 | 18 |
| 196 | Medical Treatment of the Large Prostate. 2018 , 53-73 | |
| 195 | Repurposing drugs for use against Zika virus infection. 2018 , 29, 103-115 | 15 |
| 194 | Erectile Dysfunction in Brazilian Primary Health Care: Dealing with Medicalization. 2018 , 12, 431-440 | 1 |
| 193 | A Family Based Study of Carbon Monoxide and Nitric Oxide Signalling Genes and Preeclampsia. 2018 , 32, 1-12 | 3 |
| 192 | Dietary nitrate supplementation in cardiovascular health: an ergogenic aid or exercise therapeutic?. 2018 , 314, H195-H212 | 23 |
| 191 | Sildenafil citrate use in Addis Ababa: characteristics of users and pharmacists' dispensing practices. 2018 , 40, 67-73 | 1 |
| 190 | Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation. 2018 , 26, 119-133 | 8 |
| 189 | Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. 2018 , 43, 191-216 | 1 |
| 188 | Oral bioavailability and pharmacokinetics of sildenafil citrate dry foam tablets in rats. 2018 , 5, 1510821 | 3 |
| 187 | Sildenafil crosses the placenta at therapeutic levels in a dually perfused human cotyledon model. 2018 , 219, 619.e1-619.e10 | 17 |

| | | |
|-----|--|----|
| 186 | Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents. 2018 , 12, 824 | 24 |
| 185 | Novel effect of sildenafil on hair growth. 2018 , 505, 685-691 | 10 |
| 184 | Sildenafil Citrate Liposomes for Pulmonary Delivery by Ultrasonic Nebulization. 2018 , 8, 1291 | 3 |
| 183 | Using improved Restricted Boltzmann Machines for drug-disease Prediction. 2018 , | 0 |
| 182 | Endothelial Alterations in Pulmonary Hypertension. 2018 , 439-451 | 1 |
| 181 | Biomechanical, histological, and radiological effects of different phosphodiesterase inhibitors on femoral fracture healing in rats. 2018 , 26, 2309499018777885 | 9 |
| 180 | Rational application of drug promiscuity in medicinal chemistry. 2018 , 10, 1835-1851 | 26 |
| 179 | Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms. 2018 , 15, 982-989 | 4 |
| 178 | Cardiac Physiology and Pharmacology. 2019 , 424-457.e17 | 1 |
| 177 | Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway. 2019 , 54, 1516-1526 | 11 |
| 176 | Inferring Drug-Related Diseases Based on Convolutional Neural Network and Gated Recurrent Unit. 2019 , 24, | 4 |
| 175 | Effects of PDE-5 Inhibition on the Cardiopulmonary System After 2 or 4 Weeks of Chronic Hypoxia. 2019 , 33, 407-414 | 6 |
| 174 | The potential of drug repurposing combined with reperfusion therapy in cerebral ischemic stroke: A supplementary strategy to endovascular thrombectomy. 2019 , 236, 116889 | 5 |
| 173 | Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression. 2019 , 11, | 15 |
| 172 | EK-DRD: A Comprehensive Database for Drug Repositioning Inspired by Experimental Knowledge. 2019 , 59, 3619-3624 | 2 |
| 171 | The NCATS Pharmaceutical Collection: a 10-year update. 2019 , 24, 2341-2349 | 31 |
| 170 | Advances in small-molecule therapy for managing angina pectoris in the elderly. 2019 , 20, 1471-1481 | |
| 169 | Placental effects and transfer of sildenafil in healthy and preeclamptic conditions. 2019 , 45, 447-455 | 21 |

| | | |
|-----|---|----|
| 168 | Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction. 2019 , 89, 103022 | 4 |
| 167 | Drug ReposER: a web server for predicting similar amino acid arrangements to known drug binding interfaces for potential drug repositioning. 2019 , 47, W350-W356 | 13 |
| 166 | Characterization of TPN171 metabolism in humans via ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. 2019 , 172, 302-310 | 2 |
| 165 | Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. 2019 , 62, 4979-4990 | 13 |
| 164 | Application of In Silico Drug Repurposing in Infectious Diseases. 2019 , 427-462 | |
| 163 | Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy. 2019 , 10, 531 | 64 |
| 162 | A new computational drug repurposing method using established disease-drug pair knowledge. 2019 , 35, 3672-3678 | 14 |
| 161 | Computational Drug Repurposing for Neurodegenerative Diseases. 2019 , 85-118 | 4 |
| 160 | Drug repositioning in pulmonary arterial hypertension: challenges and opportunities. 2019 , 9, 2045894019832226 | |
| 159 | Phosphodiesterases as therapeutic targets for respiratory diseases. 2019 , 197, 225-242 | 48 |
| 158 | Sildenafil for Pulmonary Arterial Hypertension. 2019 , 26, e520-e526 | 19 |
| 157 | Sildenafil for the treatment of preeclampsia, an update: should we still be enthusiastic?. 2019 , 34, 1819-1826 | 4 |
| 156 | Pharmacotherapy of obesity: Available medications and drugs under investigation. 2019 , 92, 170-192 | 98 |
| 155 | Applications of Metabolic Phenotyping in Pharmaceutical Research and Development. 2019 , 407-447 | 1 |
| 154 | Network-Based Drug Repositioning: Approaches, Resources, and Research Directions. 2019 , 1903, 97-113 | 24 |
| 153 | The exploration of novel Alzheimer's therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches. 2019 , 109, 2513-2526 | 23 |
| 152 | The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. 2019 , 7, 115-128 | 53 |
| 151 | Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil. 2019 , 9, 319-333 | 7 |

| | | |
|-----|--|---------|
| 150 | Enhanced dissolution of sildenafil citrate as dry foam tablets. 2019 , 24, 1-11 | 12 |
| 149 | In silico drug repositioning based on drug-miRNA associations. 2020 , 21, 498-510 | 11 |
| 148 | Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing. 2020 , 38, 533-547 | 11 |
| 147 | Treatment of Heart Failure with Preserved Ejection Fraction. 2020 , 568-585 | |
| 146 | Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data. 2020 , 60, 333-352 | 21 |
| 145 | Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. 2020 , 177, 5467-5488 | 34 |
| 144 | Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. <i>Nature Reviews Drug Discovery</i> , 2020 , 19, 93-111 | 64.1 77 |
| 143 | High efficacy, rapid onset nanobiosomes of sildenafil as a topical therapy for erectile dysfunction in aged rats. 2020 , 591, 119978 | 7 |
| 142 | Liquid chromatography-tandem mass spectrometric assay for TPN171 in human plasma. 2020 , 191, 113634 | 1 |
| 141 | Integration of genetic variants and gene network for drug repurposing in colorectal cancer. 2020 , 161, 105203 | 4 |
| 140 | Oleosomes Encapsulating Sildenafil Citrate as Potential Topical Nanotherapy for Palmar Plantar Erythrodysesthesia with High Ex vivo Permeation and Deposition. 2020 , 21, 310 | 5 |
| 139 | Repurposing drug molecules for new pulmonary therapeutic interventions. 2021 , 11, 1829-1848 | 6 |
| 138 | Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. 2020 , 25, | 34 |
| 137 | DDCI-01, a novel long acting phosphodiesterase-5 inhibitor, attenuated monocrotaline-induced pulmonary hypertension in rats. 2020 , 10, 2045894020939842 | |
| 136 | Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease. 2020 , 190, 111311 | 4 |
| 135 | Therapeutic Drug Development and Human Clinical Trials. 2020 , 339-358 | 1 |
| 134 | Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects. 2020 , 258, 118189 | 21 |
| 133 | Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?. 2020 , 21, | 22 |

| | | |
|-----|--|-----|
| 132 | Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. 2020 , 16, 993-1004 | 4 |
| 131 | A dynamic simulation study of FDA drug from zinc database against COVID-19 main protease receptor. 2020 , 1-17 | 10 |
| 130 | Artificial intelligence in COVID-19 drug repurposing. 2020 , 2, e667-e676 | 188 |
| 129 | Repurposing of Drugs-The Ketamine Story. 2020 , 63, 13514-13525 | 8 |
| 128 | Tree-Based QSAR Model for Drug Repurposing in the Discovery of New Antibacterial Compounds Against. 2020 , 13, | 3 |
| 127 | Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors. 2020 , 104, 104322 | 3 |
| 126 | Challenges for Drug Repurposing in the COVID-19 Pandemic Era. 2020 , 11, 588654 | 41 |
| 125 | The role of hemoglobin in nitric oxide transport in vascular system. 2020 , 5, 100034 | 5 |
| 124 | Drug Repurposing Strategy against Fungal Biofilms. 2020 , 20, 509-516 | 1 |
| 123 | Towards a roadmap to advance non-hormonal contraceptive multipurpose prevention technologies: strategic insights from key stakeholders. 2020 , 103, 289-298 | 0 |
| 122 | Repurposing of Drugs Is a Viable Approach to Develop Therapeutic Strategies against Central Nervous System Related Pathogenic Amoebae. 2020 , 11, 2378-2384 | 5 |
| 121 | Computational approaches for drug discovery against trypanosomatid-caused diseases. 2020 , 147, 611-633 | 9 |
| 120 | Next-generation drug repurposing using human genetics and network biology. 2020 , 51, 78-92 | 35 |
| 119 | Discovering Anti-Cancer Drugs Computational Methods. 2020 , 11, 733 | 52 |
| 118 | One drug to cure them all. 2020 , 22, 290-293 | 0 |
| 117 | Preeclampsia beyond pregnancy: long-term consequences for mother and child. 2020 , 318, F1315-F1326 | 36 |
| 116 | PDE5 inhibition improves cardiac morphology and function in SHR by reducing NHE1 activity: Repurposing Sildenafil for the treatment of hypertensive cardiac hypertrophy. 2021 , 891, 173724 | 2 |
| 115 | Artificial intelligence based identification of the functional role of hirudin in diabetic erectile dysfunction treatment. 2021 , 163, 105244 | 2 |

| | | |
|-----|---|----|
| 114 | Predicting Drug-Disease Associations Based on Network Consistency Projection. 2021 , 591-602 | |
| 113 | Potential Cellular Targets Associated with the Signaling of the Pulmonary Hypertension. 2021 , 435-445 | |
| 112 | Current In Silico Drug Repurposing Strategies. 2021 , 257-268 | |
| 111 | Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?. 2021 , 22, | 11 |
| 110 | New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. 2021 , 11, 627229 | 7 |
| 109 | An Alternative Pipeline for Glioblastoma Therapeutics: A Systematic Review of Drug Repurposing in Glioblastoma. 2021 , 13, | 2 |
| 108 | Wnt/ β -catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme. 2021 , | 2 |
| 107 | Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors. 2021 , 23, 1614-1623 | 3 |
| 106 | Sildenafil in Combination Therapy against Cancer: A Literature Review. 2021 , 28, 2248-2259 | 3 |
| 105 | Sildenafil: From angina to SARS-CoV-2. 2021 , | |
| 104 | Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates. 2021 , 28, 2418-2437 | 2 |
| 103 | Nitric Oxide-cGMP Pathway Modulation in an Experimental Model of Hypoxic Pulmonary Hypertension. 2021 , 26, 665-676 | 3 |
| 102 | Sildenafil in ophthalmology: An update. 2021 , | 3 |
| 101 | Genome-wide discovery of hidden genes mediating known drug-disease association using KDDANet. 2021 , 6, 50 | 1 |
| 100 | PTEN as a Therapeutic Target in Pulmonary Hypertension Secondary to Left-heart Failure: Effect of HO-3867 and Supplemental Oxygenation. 2021 , 79, 593-607 | 2 |
| 99 | The Potential Role of Sildenafil in Cancer Management through EPR Augmentation. 2021 , 11, | 5 |
| 98 | Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment. 2021 , 11, 2135-2190 | 2 |
| 97 | Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target. 2021 , | 4 |

| | | |
|----|---|----|
| 96 | Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. 2021 , 14, | 13 |
| 95 | Eco-friendly stability-indicating RP-HPTLC method for sildenafil analysis, characterization and biological evaluation of its oxidized stress degradation product. 2021 , 11, 15358 | 0 |
| 94 | The Solid State Landscape of the Sildenafil Drug. 2021 , | 0 |
| 93 | Ubiquinol ameliorates endothelial dysfunction and increases expression of miRNA-34a in a rat model of pulmonary hypertension. 2021 , 7, 23-31 | 1 |
| 92 | Integrated Multi-omics, Virtual Screening and Molecular Docking Analysis of Methicillin-Resistant USA300 for the Identification of Potential Therapeutic Targets: An In-Silico Approach. 2021 , 27, 1-21 | 2 |
| 91 | Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses. 2021 , 26, | 2 |
| 90 | Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors. 2021 , 114, 105104 | 0 |
| 89 | SARS-CoV-2 therapeutics: how far do we stand from a remedy?. 2021 , 73, 750-768 | 6 |
| 88 | Systematic drug repurposing through text mining. 2014 , 1159, 253-67 | 34 |
| 87 | Chapter 8:The Discovery of the Long-acting PDE5 Inhibitor PF-489791 for the Treatment of Pulmonary Hypertension. 2010 , 166-182 | 2 |
| 86 | A Literature-Based Knowledge Graph Embedding Method for Identifying Drug Repurposing Opportunities in Rare Diseases. | 4 |
| 85 | In Silico studies of novel Sildenafil self-emulsifying drug delivery system absorption improvement for pulmonary arterial hypertension. 2020 , 92, e20191445 | 1 |
| 84 | Medicamentos e tratamentos para a Covid-19. 2020 , 34, 7-27 | 2 |
| 83 | Computational Drug Repurposing: Current Trends. 2019 , 26, 5389-5409 | 29 |
| 82 | Natural Compounds Promoting Weight Loss: Mechanistic Insights from the Point of View of the Medicinal Chemist. 2019 , 9, 78-85 | 4 |
| 81 | Sildenafil Ameliorates Advanced Glycation End Products-Induced Mitochondrial Dysfunction in HT-22 Hippocampal Neuronal Cells. 2016 , 59, 259-68 | 6 |
| 80 | Sildenafil Citrate Does Not Reprogram Risk of Hypertension and Chronic Kidney Disease in Offspring of Preeclamptic Pregnancies in the Dahl SS/Jr Rat.. 2020 , 1, 510-520 | 2 |
| 79 | Sildenafil in pediatric pulmonary arterial hypertension. 2015 , 61, 181-92 | 16 |

| | | |
|----|--|----|
| 78 | A Retrospective Review of Infants Receiving Sildenafil. 2018 , 23, 100-105 | 5 |
| 77 | Computational drug repositioning based on side-effects mined from social media. 2, e46 | 19 |
| 76 | Sildenafil-Mediated Neuroprotection from Adult to Neonatal Brain Injury: Evidence, Mechanisms, and Future Translation. 2021 , 10, | 0 |
| 75 | Phosphodiesterase-5 (PDE-5) Inhibitors as Emergent Environmental Contaminants: Advanced Remediation and Analytical Methods. 2021 , 13, 2859 | |
| 74 | Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. 2011 , 1477-1485 | |
| 73 | Challenges and Responses. 2011 , 329-347 | |
| 72 | The need for pharmacovigilance in ophthalmic practice. 2016 , 64, 175-6 | |
| 71 | Rapid Identification and Validation of Novel Rheumatoid Arthritis Drug Treatments using an Integrative Bioinformatics Platform. | |
| 70 | Using the Encoder Embedded Framework of Dimensionality Reduction Based on Multiple Drugs Properties for Drug Recommendation. 2018 , 258-266 | 0 |
| 69 | Sildenafil Induces Cell Cycle Arrest and Apoptosis in Human Colorectal Cancer HT-29 Cells. 2018 , 7, 59-63 | 0 |
| 68 | New Drugs - From Necessity to Delivery. 2018 , 31, 69-75 | 1 |
| 67 | Genome-wide discovery of hidden genes mediating known drug-disease association using KDDANet. | |
| 66 | Histological Evaluation of the Effect of Sildenafil and Pentoxifylline on Mandibular Fracture Healing in Rats. 2019 , 4, 5-14 | |
| 65 | The effect of two phosphodiesterase inhibitors on bone healing in mandibular fractures (animal study in rats). 2020 , 46, 258-265 | 3 |
| 64 | [The place of riociguat in the treatment of patients with pulmonary arterial hypertension associated with systemic connective tissue diseases]. 2020 , 60, 92-101 | |
| 63 | Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension. 2008 , 2, 225-31 | 2 |
| 62 | A Literature-Based Knowledge Graph Embedding Method for Identifying Drug Repurposing Opportunities in Rare Diseases. 2020 , 25, 463-474 | 11 |
| 61 | Analysis of Geometric and Hemodynamic Profiles in Rat Arteriovenous Fistula Following PDE5A Inhibition.. 2021 , 9, 779043 | 0 |

| | | |
|----|--|----|
| 60 | DDIT: An Online Predictor for Multiple Clinical Phenotypic Drug-Disease Associations.. 2021 , 12, 772026 | 0 |
| 59 | Antiseizure medication discovery: Recent and future paradigm shifts.. 2022 , | |
| 58 | Sildenafil for treating patients with COVID-19 and perfusion mismatch: a pilot randomized trial.. 2022 , 26, 1 | 5 |
| 57 | Chapter 1. Introduction and Historical Overview of Drug Repurposing Opportunities. 2022 , 1-13 | 2 |
| 56 | A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism.. 2022 , 3, 100433 | 1 |
| 55 | Association of Improved Outcomes and Phosphodiesterase-5 Inhibition During Contemporary LVAD Support: End of the Beginning?. 2022 , 10, 101-103 | 0 |
| 54 | Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease.. 2021 , 1, 1175-1188 | 13 |
| 53 | Towards a general framework for innovation shaped with AI to create and transform market offerings. | 0 |
| 52 | NF- κ B Signaling and Inflammation-Drug Repurposing to Treat Inflammatory Disorders?. 2022 , 11, | 0 |
| 51 | Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing.. 2022 , 1-11 | 1 |
| 50 | The differentiation of mesenchymal bone marrow stem cells into nerve cells induced by <i>Chromolaena odorata</i> extracts. 11, 252 | |
| 49 | Molecular Docking as a Potential Approach in Repurposing Drugs Against COVID-19: a Systematic Review and Novel Pharmacophore Models.. 2022 , 1-15 | 4 |
| 48 | Combined drug triads for synergic neuroprotection in retinal degeneration. 2022 , 149, 112911 | 1 |
| 47 | Sildenafil aggravates adriamycin-induced testicular toxicity in rats; a preliminary investigation.. 2021 , 1-7 | |
| 46 | Artificial intelligence unifies knowledge and actions in drug repositioning. 2021 , | 0 |
| 45 | A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus.. 2022 , | |
| 44 | Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension.. 2022 , 12, 7393 | 1 |
| 43 | Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial Hypertension.. 2022 , 621, 121792 | 1 |

| | | | |
|----|--|------|----|
| 42 | Phenotypic drug discovery: recent successes, lessons learned and new directions. <i>Nature Reviews Drug Discovery</i> , | 64.1 | 5 |
| 41 | Prospective Medicines against the Widespread, Emergent and Multidrug-Resistant Opportunistic Fungal Pathogen <i>Candida auris</i> : A Breath of Hope.. 2022 , 22, | | |
| 40 | Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies. | | 1 |
| 39 | New Possibilities in Heart Failure: The Effects of Tadalafil on Diastolic Function in Patients Undergoing Robot-Assisted Radical Prostatectomy. 2022 , 12, 5629 | | 0 |
| 38 | The differentiation of mesenchymal bone marrow stem cells into nerve cells induced by <i>Chromolaena odorata</i> extracts. 11, 252 | | |
| 37 | Repurposing therapeutics for malignant pleural mesothelioma (MPM) [Updates on clinical translations and future outlook. 2022 , 304, 120716 | | 1 |
| 36 | System and network biology-based computational approaches for drug repositioning. 2022 , 267-290 | | 2 |
| 35 | Pharmacokinetics, mass balance, and metabolism of [¹⁴ C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension. | | 1 |
| 34 | Hotspots and frontiers in pulmonary arterial hypertension research: a bibliometric and visualization analysis from 2011 to 2020. 2022 , 13, 14667-14680 | | 0 |
| 33 | Translational Medicine [The Bridging Discipline. Role and Tools in the Drug Development Process. 2022 , 119-138 | | |
| 32 | 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879 | | 18 |
| 31 | 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. | | 58 |
| 30 | A Review on Computer-aided Chemogenomics and Drug Repositioning for Rational COVID -19 Drug Discovery. | | 1 |
| 29 | Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors. 2022 , 15, 1024 | | |
| 28 | Advanced formulations and nanotechnology-based approaches for pulmonary delivery of sildenafil: A scoping review. 2022 , 350, 308-323 | | 0 |
| 27 | Genomic Approaches for Drug Repositioning. 2022 , 49-72 | | 0 |
| 26 | Patents and applications of N-sulfonated N-heterocycles. 2022 , 447-496 | | 0 |
| 25 | Design, synthesis and chemoinformatic studies of new thiazolopyrimidine derivatives as potent anticancer agents via phosphodiesterase-5 inhibition and apoptotic inducing activity. 2023 , 1272, 134216 | | 2 |

- 24 Sildenafil during the 2nd and 3rd Trimester of Pregnancy: Trials and Tribulations. **2022**, 19, 11207 1
- 23 PDE2A Inhibition Enhances Axonal Sprouting, Functional Connectivity and Recovery after Stroke. JN-RM-0730-22
- 22 Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease. 14, 1
- 21 Skin cancer signal associated with phosphodiesterase inhibitors: gaining insight through the FDA pharmacovigilance database. 1-9 0
- 20 Optimizing drug discovery: An opportunity and application with reverse translational research. **2023**, 6, 100074 0
- 19 Polymeric hydrogel forming microneedle-mediated transdermal delivery of sildenafil citrate from direct-compressed tablet reservoir for potential improvement of pulmonary hypertension therapy. **2022**, 122549 0
- 18 Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials. **2023**, 0
- 17 Protective Effects of Rifampicin and Its Analog Rifampicin Quinone in a Mouse Model of Obesity-Induced Type 2 Diabetes. 0
- 16 Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics. **2023**, 242, 108337 0
- 15 Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study. **2023**, 24, 669 0
- 14 Cerebral haemodynamic response to somatosensory stimulation in preterm lambs is enhanced following sildenafil and inhaled nitric oxide administration. 14, 0
- 13 Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis. 14, 0
- 12 Theranostic applications of nanoemulsions in pulmonary diseases. **2023**, 177-216 0
- 11 Drug Repurposing: An Advance Way to Traditional Drug Discovery. **2023**, 1-25 0
- 10 Drug Polypharmacology Toward Drug Repurposing. **2023**, 27-36 0
- 9 Sildenafil reduces bisphosphonate-induced jaw osteonecrosis in rats. 0
- 8 Levels of elements in selected food substances that support usage in the management and treatment of erectile dysfunction. 026010602211099 0
- 7 Anti-Tuberculosis Mur Inhibitors: Structural Insights and the Way Ahead for Development of Novel Agents. **2023**, 16, 377 0

- 6 Drug-Repurposing Screening Identifies a Gallic Acid Binding Site on SARS-CoV-2 Non-structural Protein 7. **2023**, 6, 578-586 ○
- 5 PBPK-based dose finding for sildenafil in pregnant women for antenatal treatment of congenital diaphragmatic hernia. 14, ○
- 4 Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction. ○
- 3 CADD for Cancer Therapy: Current and Future Perspective. **2023**, 325-363 ○
- 2 Clinical side-effects based drug repositioning for anti-epileptic activity. 1-12 ○
- 1 Immunomodulatory, apoptotic and anti-proliferative potentials of sildenafil in Ehrlich ascites carcinoma murine model: In vivo and in silico insights. **2023**, 119, 110135 ○